 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Reata Pharmaceuticals
RETA
conference date: may 10, 2023 @ 5:30 AM Pacific Time
Reata Pharmaceuticals Announces FDA Approval of Skyclarys (Omavaloxolone) [February 28, 2023 at reatapharma.com]
Reata Pharmaceuticals: Buy While Waiting [January 3, 2023 at Seeking Alpha]
Reata Bardoxolone Trial Success Likely, But Still Just A Hold [May 24, 2019 at Seeking Alpha]
Reata Pharmaceuticals a Buy [Feb. 14, 2018 at Seeking Alpha]
| 2023 | |||
| Reata Pharmaceuticals 2022 10-K |
Reata Pharmaceuticals Q1 2023 |
||
| Feb. 24, 2023 | May 10, 2023 | ||
| 2022 | |||
| Reata Pharmaceuticals Q4 2021 |
Reata Pharmaceuticals Q1 2022 |
Reata Pharmaceuticals Q2 2022 |
Reata Pharmaceuticals Q3 2022 |
| Feb. 28, 2022 | May 10, 2022 | Aug. 8 2022 | Nov. 8, 2022 |
| 2021 | |||
| Reata Pharmaceuticals Q4 2020 |
Reata Pharmaceuticals Q1 2021 |
Reata Pharmaceuticals Q2 2021 |
Reata Pharmaceuticals Q3 2021 |
| March 1, 2021 | May 6, 2021 | Aug. 9, 2021 | Nov. 8, 2021 |
| 2020 | |||
| Reata Pharmaceuticals Q4 2019 |
Reata Pharmaceuticals Q1 2020 |
Reata Pharmaceuticals Q2 2020 |
Reata Pharmaceuticals Q3 2020 |
| Feb. 19, 2020 | May 11, 2020 | Aug. 10, 2020 | Nov. 9, 2020 |
| 2019 | |||
| Reata Pharmaceuticals Q4 2018 |
Reata Pharmaceuticals Q1 2019 |
Reata Pharmaceuticals Q2 2019 |
Reata Pharmaceuticals Q3 2019 |
| Feb. 28, 2019 | May 9, 2019 | Aug. 8, 2019 | Nov. 12, 2019 |
2018 |
|||
March 2, 2018 |
May 9, 2018 |
August 8, 2018 |
Nov. 7, 2018 |
Reata Pharmaceuticals (RETA) is a clinical-stage biotechnology company specializing in therapies to improve mitochondrial functions for rate diseases, including chronic kidney diseases.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CDTX |
| CLDX |
| FATE |
| GILD |
| GLYC |
| INCY |
| INO |
| IONS |
| MCHP |
| MRNA |
| PLX |
| REGN |
| SAGE |
| SYRS |
| TSTV |
| VRTX |
| VSTM |
| WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2023 William P. Meyers